Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

7 treatments under study, led by Fluorouracil

Related Conditions

Often studied with 20 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Phase 1 (1)
Phase 2 (1)

Trial Status

Completed2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT02333188Phase 1Completed

Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer

NCT02042443Phase 2CompletedPrimary

Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery

Showing all 2 trials

Research Network

Common Treatments

  • Fluorouracil2
  • Leucovorin Calcium2
  • Laboratory Biomarker Analysis2
  • Capecitabine1
  • Irinotecan Hydrochloride1

Active Sponsors

  • National Cancer Institute (NCI)2
  • University of Chicago1

Top Investigators

Related Conditions

  • Stage Iiia Gallbladder Cancer2
  • Stage Iiib Gallbladder Cancer2
  • Bclc Stage C Adult Hepatocellular Carcinoma1
  • Recurrent Adult Liver Carcinoma1
  • Malignant Gastrointestinal Neoplasm1

Activity Timeline